Sugi Predict

Sugi Predict / Compounds / Mandelic Acid, Methyl Ester

Mandelic Acid, Methyl Ester

Mandelic Acid, Methyl Ester

SCHEMBL186899

COC(=O)[C@@H](O)c1ccccc1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.67
▸ LMNA P02545 6/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ CES2 O00748 1/20 0.52
▸ CES1 P23141 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ PTGS2 P35354 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ CHRM2 P08172 2/20 0.47
▸ CHRM1 P11229 2/20 0.47
▸ CHRM4 P08173 1/20 0.47
▸ CHRM5 P08912 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mandelic Acid, Methyl Ester SCHEMBL28228867 1.00 KMT2A (0.67) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL186900 1.00 KMT2A (0.67) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL186898 1.00 KMT2A (0.67) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL7701656 0.98 KMT2A (0.64) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL27579970 0.98 KMT2A (0.64) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL8082961 0.98 KMT2A (0.64) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL7512539 0.96 KMT2A (0.62) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL29214409 0.94 KMT2A (0.60) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL30951860 0.92 KMT2A (0.63) KMT2ALMNAMAPK1CES2CES1
SCHEMBL6240606 0.92 KMT2A (0.58) KMT2ALMNAMAPK1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 — — US claimed
CN-106119224-B Esterase EstP00714 and coding gene and application thereof 中国科学院南海海洋研究所 2019-12-10 — — CN claimed
CN-108623452-A A kind of synthetic method of intermediate S- (+) -2,2- dimethyl cyclopropane carboxylic acids 徐州得铸生物科技有限公司 2018-10-09 — — CN claimed
CN-106119224-A A kind of esterase EstP00714 and encoding gene thereof and application 中国科学院南海海洋研究所 2016-11-16 — — CN claimed
CN-102719497-B Method for preparing methyl (S)-(+)-mandelate by microbial transformation of methyl benzoylformate UNIV ZHEJIANG TECHNOLOGY 2013-12-04 — — CN claimed
CN-102719497-A Method for preparing methyl (S)-(+)-mandelate by microbial transformation of methyl benzoylformate UNIV ZHEJIANG TECHNOLOGY 2012-10-10 — — CN claimed
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2025-10-09 — — US disclosed
US-20250214960-A1 COMPOUNDS HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF SHANGHAI BIOPARTNERSX CO., LTD. (CN) 2025-07-03 — — US disclosed
CN-112384515-B Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors 因赛特公司 2024-12-10 — — CN disclosed
CN-118201917-A Compound with degradation GSPT1 activity and application thereof 上海美志医药科技有限公司 2024-06-14 — — CN disclosed
WO-2024105203-A1 NOVEL ANTI-SENESCENCE COMPOUNDS VITEXIA APS (DK) 2024-05-23 — — WO disclosed
CN-117903140-A Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors 因赛特公司 2024-04-19 — — CN disclosed
CN-113166156-B Tyrosine kinase inhibitors, compositions and methods 贝达药业股份有限公司 2024-02-27 — — CN disclosed
WO-1996001831-A1 HETEROAROMATIC DIPHOSPHINES AS CHIRAL LIGANDS ITALFARMACO SUD S.P.A. (IT) 1996-01-25 — — WO disclosed
WO-1995029150-A1 SYNTHESIS OF PROTOTYPES FOR RENIN INHIBITORS CIBA-GEIGY AG (CH) 1995-11-02 — — WO disclosed
WO-1995003285-A1 1,5-BENZODIAZEPINE DERIVATIVES USEFUL AS CCK OR GASTRIN ANTAGONISTS GLAXO SPA (IT) 1995-02-02 — — WO disclosed
US-5280122-A Resolution of 2-benzyl-4-piperidone-succinic acid PFIZER INC. (US) 1994-01-18 — — US disclosed
US-5248610-A Transesterification CHISSO CORPORATION (JP) 1993-09-28 — — US disclosed
EP-0459455-A2 Process for producing optically active alpha-hydroxyesters CHISSO CORPORATION (JP) 1991-12-04 — — EP disclosed
US-4978744-A Synthesis of dolastatin 10 ARIZONA BOARD OF REGENTS (US) 1990-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214960-A1 COMPOUNDS HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF GSPT1, GSS, GSAP KMT2A 4313/4885LMNA 2927/4885MAPK1 4084/4885
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 KMT2A 1923/4885LMNA 4020/4885MAPK1 2114/4885
US-11760750-B1 Process for preparing levoketoconazole KHK, KYAT3, PLK3 KMT2A 1550/4885LMNA 1990/4885MAPK1 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.